Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Bioject Medical Technologies Inc. Stories

2014-03-20 16:26:49

TIGARD, Ore., March 20, 2014 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a developer and manufacturer of needle-free injection therapy systems, today announced it is seeking to restructure its balance sheet, in order to secure necessary operating capital. After attempts to obtain necessary operating capital from third parties over a period of twelve months were unsuccessful, Bioject received an advance on March 17, 2014, of $500,000 from two of its directors,...

2014-01-22 08:29:45

Products include the Biojector® 2000, Vial Adapter and Bioject® Zetajet(TM) TIGARD, Ore., Jan. 22, 2014 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that Meditrend International, Bioject's Australian/New Zealand Distributor has received the Australian Register of Therapeutic Goods Certificate for the Biojector Needle-free injection Management System (Biojector® 2000),...

2013-10-30 08:31:57

TIGARD, Ore., Oct. 30, 2013 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into a distribution agreement with FlashMed Inc. a medical supply company based in Quito, Ecuador. FlashMed will be the exclusive distributor of the Biojector® 2000 needle-free injection system and the Bioject® ZetaJet(TM) portable injector products in Ecuador. "We are very...

2013-10-23 08:30:50

Agreement advances Bioject's global market expansion strategy through Fondaco's established medical device marketing and distribution networks in countries including Singapore, Malaysia and Indonesia TIGARD, Ore., Oct. 23, 2013 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that it has entered into a distribution agreement with Fondaco PTE, LTD, a premier medical supplies...

2008-07-17 09:01:20

Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free injection therapy systems, today announced that the Biojector(R) 2000 (B2000) was used in Vical Inc.'s (Vical) first Phase 1 human trial of H5N1 pandemic influenza DNA vaccines formulated with Vical's Vaxfectin(R) adjuvant. Data were presented today by Vical at the IBC Life Sciences Next Generation Vaccines conference held in Maryland. The double-blind, placebo-controlled, dose-escalation trial was...